|
WO2018007624A1
|
|
Enzalutamide derivatives for the treatment of prostate and breast cancer
|
|
WO2017042839A1
|
|
Novel eltrombopag salt and preparation thereof
|
|
WO2017033212A1
|
|
Preparation of sacubitril and salt thereof and novel compounds used in the process
|
|
GB201611917D0
|
|
Pharmaceutical agents
|
|
GB201611916D0
|
|
Pharmaceutical agents
|
|
WO2016203500A2
|
|
Preparation of sacubitril or salt thereof and novel intermediates in the preparation of sacubitril
|
|
WO2016162888A1
|
|
Process for preparing pharmaceutical grade ferric citrate
|
|
GB201511246D0
|
|
Pharmaceutical formulation
|
|
IS2977B
|
|
Process for the preparation of intermediates useful in the synthesis of eluxadoline
|
|
US2015299101A1
|
|
Solid state forms of tapentadol salts
|
|
EP2983649A1
|
|
Pemetrexed formulation
|
|
WO2014118809A1
|
|
Pharmaceutical composition with linezolid
|
|
WO2014083139A1
|
|
Novel amorphous form of ticagrelor
|
|
WO2013182625A1
|
|
Pharmaceutical formulation with propargylamine compound
|
|
MX2014006190A
|
|
Novel crystalline form of ticagrelor and process for the preparation thereof.
|
|
AU2012270017A1
|
|
Improved process for preparing cyclopentylamine derivatives and intermediates thereof
|
|
WO2012146978A2
|
|
A novel process for the preparation of tapentadol or a pharmaceutically acceptable salt thereof
|
|
WO2012085665A2
|
|
Novel processes for preparing triazolo[4,5-d]pyrimidine derivatives and intermediates thereof
|
|
WO2012063126A2
|
|
Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material
|
|
WO2012004677A1
|
|
Solid state forms of etoricoxib salts
|
